Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies.

Autor: Nolan RP; Halozyme Therapeutics, Inc., San Diego, CA, USA., Kang DW; Halozyme Therapeutics, Inc., San Diego, CA, USA., Maneval DC; Formerly with Halozyme Therapeutics, Inc., San Diego, CA, USA., Knowles SP; Formerly with Halozyme Therapeutics, Inc., San Diego, CA, USA., LaBarre MJ; Halozyme Therapeutics, Inc., San Diego, CA, USA., Printz MA; Halozyme Therapeutics, Inc., San Diego, CA, USA. Electronic address: mprintz@halozyme.com.

Publikováno v: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Oct; Vol. 374, pp. 369-383. Date of Electronic Publication: 2024 Aug 23.

Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration.

Autor: Printz MA; Halozyme Therapeutics, Inc., 11388 Sorrento Valley Rd, San Diego, California, 92121, USA. publications@halozyme.com., Sugarman BJ; Formerly with Halozyme Therapeutics, Inc., San Diego, California, USA., Paladini RD; Formerly with Halozyme Therapeutics, Inc., San Diego, California, USA., Jorge MC; Formerly with Halozyme Therapeutics, Inc., San Diego, California, USA., Wang Y; Halozyme Therapeutics, Inc., 11388 Sorrento Valley Rd, San Diego, California, 92121, USA., Kang DW; Halozyme Therapeutics, Inc., 11388 Sorrento Valley Rd, San Diego, California, 92121, USA., Maneval DC; Formerly with Halozyme Therapeutics, Inc., San Diego, California, USA., LaBarre MJ; Halozyme Therapeutics, Inc., 11388 Sorrento Valley Rd, San Diego, California, 92121, USA.

Publikováno v: The AAPS journal [AAPS J] 2022 Oct 20; Vol. 24 (6), pp. 110. Date of Electronic Publication: 2022 Oct 20.

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer.

Autor: Kang DW; Halozyme Therapeutics, Inc., San Diego, CA, United States of America., Bittner B; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Sugarman BJ; Formerly with Halozyme Therapeutics, Inc., San Diego, CA, United States of America., Zepeda ML; Formerly with Halozyme Therapeutics, Inc., San Diego, CA, United States of America., Printz MA; Halozyme Therapeutics, Inc., San Diego, CA, United States of America.

Publikováno v: PloS one [PLoS One] 2021 Jul 22; Vol. 16 (7), pp. e0254765. Date of Electronic Publication: 2021 Jul 22 (Print Publication: 2021).